ALK and non-small cell lung carcinoma: For example, brigatinib, a next-generation selective ALK inhibitor, has demonstrated substantial activity in ALK-positive NSCLC pretreated with crizotinib, particularly in cases exhibiting ALK-dependent resistance mechanisms [89].